2026 Healthcare Investment Trends

PwC's Next in Health

PwC's Next in Health
2026 Healthcare Investment Trends
Feb 09, 2026 Season 6 Episode 2

From the JPM Healthcare Conference in San Francisco, Glenn Hunzinger, PwC’s Health Industries Leader, speaks with Jeremy Gelber, Partner at Vitruvian Partners, and Claire Love, Principal in PwC’s Deals Strategy practice to explore where healthcare investment momentum is building for 2026, how technology is reshaping value creation, and what investors are watching as care models, consumer behavior, and capital deployment continue to evolve.

Discussion highlights:

  • Where technology and AI are delivering near term returns by improving efficiency, reducing administrative friction, and streamlining care delivery and payment
  • Why women’s health is gaining attention as an underinvested growth opportunity, driven by unmet need, changing consumer expectations, and attractive long term economics
  • How regulatory uncertainty is influencing investment decisions, increasing the importance of scenario planning and flexibility
  • Where deal activity is expected to pick up in 2026 across healthcare subsectors, including healthcare IT, pharma services, medtech, diagnostics, and biotech
  • How consumer trust, access to health data, and evolving behavior are shaping future care models and investment priorities

Speakers:

Glenn Hunzinger, US Health Industries Leader, PwC
Jeremy Gelber, Partner, Vitruvian Partners
Claire Love, Deals Strategy Principal, PwC

This episode is also available as a video on our website: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast/2026-healthcare-investment-trends.html 


For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

Episode Artwork 2026 Healthcare Investment Trends 24:04 Episode Artwork Where will growth emerge in health over the next 10 years? 19:55 Episode Artwork Deals Outlook 2026: What’s ahead for medtech 9:19 Episode Artwork Deals Outlook 2026: What’s ahead for health services 8:57 Episode Artwork Deals Outlook 2026: What’s ahead for pharma and life sciences 11:14 Episode Artwork Reinventing Healthcare - Seizing the $1 Trillion Breakthrough 33:48 Episode Artwork The One Big Beautiful Bill: What It Means for the Future of U.S. Healthcare 15:23 Episode Artwork Strategic Dealmaking in Health: Navigating Midyear Trends in 2025 19:39 Episode Artwork Taking a closer look at the Most Favored Nation Pricing Executive Order 16:47 Episode Artwork Navigating the FDA disruption: 4 key actions for pharma 10:05 Episode Artwork Strategic Shifts: Navigating China's Biotech Boom and Its Impact on US Pharma 11:46 Episode Artwork Navigating Healthcare’s Next Chapter Under the Trump Administration 28:08 Episode Artwork Next in Pharma: The 2025 Outlook—The Future is Now 21:34 Episode Artwork Next in Health: The 2025 Outlook for Health Services 30:57 Episode Artwork Health Industries: U.S. Deals Outlook for 2025 and Beyond 25:18 Episode Artwork PwC’s 2024 US Healthcare Climate Survey 14:57 Episode Artwork PwC's U.S. Healthcare Consumer Insights and Engagement Survey 20:40 Episode Artwork Next in medtech: Unlocking future growth in 3 strategic steps 13:14 Episode Artwork Election Impact: What to expect for the Health Industry 17:04 Episode Artwork Boardroom essentials: Securing a seat on an emerging company board 16:11 Episode Artwork PwC's 2025 Medical cost trend report reveals rising healthcare costs 21:54 Episode Artwork The importance of physician enablement to our health ecosystem 18:03 Episode Artwork How emerging companies are navigating growth in the health industry 21:13 Episode Artwork 2024 Outlook: Healthcare's big squeeze and the way out 17:55 Episode Artwork Reinventing for returns: what's next in pharma? 13:56